The UK and US have agreed to a key trade agreement that will keep zero duties on UK pharmaceutical products entering the US market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to raise expenditure on medicines through the NHS. This move secures that import taxes on these vital exports will remain at nothing for a period of 36 months.
This agreement follows recent statements to hike tariffs on branded drug imports, with figures discussed up to double the cost.
"This deal between the UK reinforces the international landscape for new treatments and brings much-needed equity to transatlantic drug exports," an announcement noted.
Commercial Impact
Drugs constitute one of the Britain's largest export categories to the America, which is clearly the primary destination for leading companies like GSK and AstraZeneca.
Export figures show that in the year to the end of the third quarter, the UK sold medicines valued at over eleven billion pounds to the US. This amount made up 17.4% of total UK exports in that timeframe.
"This agreement safeguards employment, boosts capital expenditure and paves the way for the UK to become a international leader for biotech and pharma," a government official stated.
Detailed NHS Changes
The deal involves several specific changes from the United Kingdom:
- Price Threshold Increase: The UK will raise the cost ceiling at which it deems new treatments to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a target to double overall public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The sum manufacturers must refund to the NHS to control costs will be capped at fifteen percent. Previously, repayments exceeded 20%.
Broader Context
The pact comes amid a ongoing dispute between the drug companies and the UK government over medicine costs and approval rates.
This friction were intensified by assertions that US patients were charged several times more for the equivalent treatments than consumers in the other developed nations.
In recent months, several large pharmaceutical investments in the UK have been halted or cancelled, while substantial expansions have been directed toward projects in the United States.
One official acknowledged that the NHS must spend more on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
